The Joint Venture with Novartis is a mess - werkgeversreview Anonieme werknemer bij GSK

3,0
9 jun 2015
Anonieme werknemer
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht

Pluspunten

Compensation, Big Brands, OTC Switch capability

Minpunten

The Joint Venture with Novartis is all about cutting costs. The new GSK will be way too lean. I fear the GSK I know and love will be long gone in a few months. The transition will be long and difficult. Many things will fall trought the cracks and GSK will be less customer focused and even more focused on saving a buck. The poor performance of Big Pharma has made life difficult for Consumer Healthcare as we need to help the broader company keep the dividends high.

Ontdek andere reviews over GSK

5,0
6 mei 2026
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht

Pluspunten

Development Pay People Expertise Coaching

Minpunten

Site management turnover lead to stability issues

1,0
9 jun 2026
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht

Pluspunten

Fast paced work and a lot of very driven co-workers that are passionate about the work they do and delivering medicines to patients

Minpunten

re-organization decimated the company culture. takes a long time to move up with the company. pay is considerably less compared to what other companies pay for role.

Bekijk reviews op: Nuttig|Beoordeling|Datum|Alle